Human nature meets technology in MedTech sales

Tern plc

Sales teams are asked to master products that change lives, yet the way they are trained rarely matches the complexity or urgency of the task. The numbers tell a familiar story, long onboarding times, high turnover, and widespread target misses. But beneath the statistics lies a deeper truth: much of what is taught simply does not stick.

The core issue is human nature itself. Our brains are wired to forget what we do not actively apply. Traditional sales education, the manuals, the workshops, the static presentations, leans on outdated methods that assume information can be absorbed through repetition.

The shift now underway is about changing how people learn. Artificial Intelligence, Mixed Reality, and Augmented Reality are converging to create environments where knowledge becomes experience. Instead of reading about a medical device, a sales representative can manipulate it holographically, exploring every function and feature in three dimensions. Instead of rehearsing sales pitches in abstract, they can engage with realistic AI-driven simulations that replicate the tension and unpredictability of real clinical conversations.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search